Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood Ther­a­peu­tics

Five years ago, Roche tout­ed a clin­i­cal suc­cess for one of its mid-stage car­dio pro­grams, re­port­ing the in­ves­ti­ga­tion­al med showed promise in re­duc­ing heart dam­age …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER